Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism
- Conditions
- Secondary Hypogonadism
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT01739595
- Locations
- 🇺🇸
Coastal Clinical Research, Mobile, Alabama, United States
🇺🇸Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States
🇺🇸Rancho Cucamonga Clinical Trials, Rancho Cucamonga, California, United States
Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis
- First Posted Date
- 2012-11-19
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01728454
Extension of Study ZPV-200
- Conditions
- Uterine Fibroids
- Interventions
- Drug: telepristone acetate 12 mgDrug: telepristone acetate 3 mgDrug: telepristone acetate 6 mgDrug: telepristone acetate 24 mg
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01631903
Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism
- Conditions
- Effect of Treatment on Bone Mineral Density
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT01619683
Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 499
- Registration Number
- NCT01534208
- Locations
- 🇺🇸
IRC Clinics, Towson, Maryland, United States
🇺🇸Meridien Research, St. Petersburg, Florida, United States
🇺🇸Breco Research, Sugar Land, Texas, United States
Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT01532414
- Locations
- 🇺🇸
Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States
🇺🇸Coastal Clinical Research, Mobile, Alabama, United States
🇺🇸SC Clinical Research, Garden Grove, California, United States
Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01451424
- Locations
- 🇺🇸
Advances in Health, Houston, Texas, United States
🇺🇸Cetero Research, Miami Gardens, Florida, United States
A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203
- Conditions
- HypogonadismLow Testosterone
- Interventions
- Drug: Androxal (enclomiphene citrate)
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2013-05-17
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01386567
The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)
- Conditions
- Secondary Hypogonadism
- Interventions
- Drug: Androxal (enclomiphene citrate)
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01386606
- Locations
- 🇺🇸
Cetero Research, San Antonio, Texas, United States
🇺🇸Centex Research, Houston, Texas, United States
Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism
- Conditions
- Secondary Hypogonadism
- Interventions
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT01270841
- Locations
- 🇺🇸
Paradigm Clinical Inc., Garden Grove, California, United States
🇺🇸Northern California Research Corp, Sacramento, California, United States
🇺🇸Jed Kaminetsky, New york, New York, United States